Evidence map›Paper›PMID 32285623›Full record

Observational studyBrain and behavior2020

Perampanel in brain tumor-related epilepsy: Observational pilot study.

Marta Maschio, Alessia Zarabla, Andrea Maialetti, Diana Giannarelli, Tatiana Koudriavtseva, Veronica Villani, Silvana Zannino

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Brain and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Review
  6. Observational
  7. Cancer Neuroscience: Decoding Neural Circuitry in Tumor Evolution for Targeted Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  8. Review
  9. Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Marta MaschioRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - Center for Tumor-Related Epilepsy - UOSD Neuroncology, Rome, Italy.ORCID 0000-0002-3075-4108
Alessia ZarablaRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - Center for Tumor-Related Epilepsy - UOSD Neuroncology, Rome, Italy.
Andrea MaialettiRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - Center for Tumor-Related Epilepsy - UOSD Neuroncology, Rome, Italy.
Diana GiannarelliRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - Biostatistic Unit, Rome, Italy.
Tatiana KoudriavtsevaRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - UOSD Neuroncology, Rome, Italy.
Veronica VillaniRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - UOSD Neuroncology, Rome, Italy.
Silvana ZanninoRegina Elena Institute for Hospitalization and Care Scientific, IRCCS - UOSD Neuroncology, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITOasi Maria SS · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePossible loss of efficacy and potential interactions between antiepileptic drugs (AEDs) and chemotherapy could complicate the management of patients with brain tumor-related epilepsy (BTRE) that may expose patients to an increased risk of adverse events. Perampanel (PER) is a highly selective, noncompetitive, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptor antagonist. This study evaluates the effectiveness, QoL, cognition, and mood of PER in add-on therapy in BTRE patients. MATERIAL AND

methodsObservational pilot study on the effectiveness of PER as add-on therapy in BTRE patients with uncontrolled seizures with a 6-month follow-up.

resultsWe recruited 26 BTRE patients. During the follow-up, 16 underwent chemotherapy and 11 radiotherapy; 11 had disease progression. Five patients dropped out. Mean daily PER dosage was 6.6 mg in the 21 patients who completed the follow-up and 6.4 mg in the ITT population. The mean number of seizures/month decreased from 10.8 ± 15.03 at baseline to 1.7 ± 4.34 in the 21 patients who reached the final follow-up. Responder rate was 88.4%: Eight patients were seizure-free, 15 had ≥50% seizure reduction, and 3 remained stable. Four patients (15.4%) reported AEs: 2 required PER dose reduction, and 2 dropped out. Neuropsychological, mood, and QoL questionnaires were not statistically different compared to baseline. There were no significant differences in seizure control in patients with/without IDH1 mutation and with/without MGMT methylation.

conclusionsPerampanel proved to be effective on seizure control in BRTE patients and to be well tolerated without negative effects on cognition and QoL. Perampanel could be a valid therapeutic option in BTRE.

Indexed as

Brain NeoplasmsEpilepsyAnticonvulsantsHumansNitrilesPilot ProjectsPyridonesQuality of LifeTreatment OutcomeAnticonvulsantsNitrilesperampanelPyridonesantiepileptic drugsbrain tumorsBTREepilepsymolecular factorsperampanelQoLresponder rate

Identifiers

PMID32285623
PMCPMC7303381
OpenAlexW3015520878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.